Join to View Full Profile
13330 Usf Laurel DrTampa, FL 33612
Phone+1 813-974-3541
Fax+1 813-974-9145
Dr. Robertson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of South Florida MorsaniResidency, Neurology, 2008 - 2012- University of South Florida College of MedicineClass of 2008
Certifications & Licensure
FL State Medical License 2012 - 2028
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR (Complete), Allscripts, 2013, 2015-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013, 2015-2017
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2013, 2015-2017
Clinical Trials
- Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients Start of enrollment: 2014 Mar 01
- A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2) Start of enrollment: 2019 Jul 22
Roles: Principal Investigator
Publications & Presentations
PubMed
- The TRaditional versus Early Aggressive Therapy for Multiple Sclerosis (TREAT-MS) trial: design and baseline characteristics of participants.Ellen M Mowry, Peiqing Qian, William Meador, Sharon Lynch, Ram Narayan
Contemporary Clinical Trials. 2025-12-01 - 8 citationsFive-Year Safety and Efficacy Outcomes with Ofatumumab in Patients with Relapsing Multiple Sclerosis.Stephen L Hauser, Jeffrey A Cohen, Jérôme de Sèze, Sven G Meuth, Paul S Giacomini
Neurology and Therapy. 2025-10-01 - 4 citationsReal-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients.Yang Mao-Draayer, Amit Bar-Or, Konstantin Balashov, John Foley, Kyle Smoot
Advances in Therapy. 2025-01-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
